ABSTRACT

Androgen deprivation therapy (ADT) is the standard treatment of metastatic prostate cancer. ADT, can be applied in the form of medical or surgical castration and in appropriate, carefully selected patients as bicalutamide monotherapy. Hormonal treatment can be done as intermittant, maximal androjen blockage and early/ late. Although patients who have recurrence are resistant to castration, they can respond to secondary hormonal manipulations. Seconder hormonal manipulations are antiandrogen withdrawal, change of antiandrogen, addition of adrenolytics. Newly developed second generation antiandrogen MDV3100 and CYP17 enzyme inhibitor abirateron acetate are promising drugs.